Patents by Inventor Frank Striggow

Frank Striggow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10670576
    Abstract: The present invention refers to a device for measuring impedance in organotypic tissue comprising at least one recording chamber with a liquid permeable membrane supporting the organotypic tissue, at least one bottom electrode and at least one top electrode, wherein the liquid permeable membrane divides the recording chamber into a top chamber and a bottom chamber, wherein at least the bottom chamber contains culture medium for the organotypic tissue, and the bottom electrode(s) is/are located in the bottom chamber and the top electrode(s) is/are located in the top chamber, and wherein the organotypic tissue is located between the bottom electrode(s) and the top electrode(s). The present invention also refers to the use of the device according to the present invention for measuring impedance in organotypic tissue.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: June 2, 2020
    Assignee: Universität Leipzig
    Inventors: Andrea Robitzki, Andrée Rothermel, Heinz-Georg Jahnke, Ina Sternberger, Frank Striggow, Till Mack
  • Publication number: 20170191980
    Abstract: The present invention refers to a device for measuring impedance in organotypic tissue comprising at least one recording chamber with a liquid permeable membrane supporting the organotypic tissue, at least one bottom electrode and at least one top electrode, wherein the liquid permeable membrane divides the recording chamber into a top chamber and a bottom chamber, wherein at least the bottom chamber contains culture medium for the organotypic tissue, and the bottom electrode(s) is/are located in the bottom chamber and the top electrode(s) is/are located in the top chamber, and wherein the organotypic tissue is located between the bottom electrode(s) and the top electrode(s). The present invention also refers to the use of the device according to the present invention for measuring impedance in organotypic tissue.
    Type: Application
    Filed: January 18, 2017
    Publication date: July 6, 2017
    Applicant: Universität Leipzig
    Inventors: Andrea ROBITZKI, Andrée Rothermel, Heinz-Georg Jahnke, Ina Sternberger, Frank Striggow, Till Mack
  • Patent number: 9527894
    Abstract: Disclosed herein are methods for identifying an agent for treating or preventing neurogenerative disease and to methods for recapitulating tauopathies using a tau protein that includes at least four different mutations that cause the condition frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and to nucleic acids encoding the tau protein.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: December 27, 2016
    Assignee: Universitaet Leipzig
    Inventors: Andrea Robitzki, Heinz-Georg Jahnke, Dana Krinke, Frank Striggow, Till Mack
  • Publication number: 20140162306
    Abstract: The present invention relates to a tau protein comprising at least four different mutations selected from group consisting of mutations which cause the condition frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and to nucleic acids encoding said tau protein. The invention further pertains to methods for identifying an agent for treating or preventing neurogenerative disease, and to methods for recapitulating tauopathies.
    Type: Application
    Filed: April 28, 2011
    Publication date: June 12, 2014
    Applicant: Universitaet Leipzig
    Inventors: Andrea Robitzki, Heinz-Georg Jahnke, Dana Krinke, Frank Striggow, Till Mack
  • Publication number: 20120258960
    Abstract: The invention relates to compounds of the general formula (1) or the acid addition salts thereof with organic and/or inorganic acids; as well as to the use of the compounds of the general formula (1) in medicine.
    Type: Application
    Filed: August 26, 2010
    Publication date: October 11, 2012
    Applicant: IMTM GMBH
    Inventors: Siegfried Ansorge, Ute Bank, Karsten Nordhoff, Peter Roehnert, Sofia Stefin, Frank Striggow, Michael Taeger
  • Patent number: 8263636
    Abstract: The present invention relates to substances capable of specifically inhibiting Ala-p-nitroanilide-cleaving peptidases and Gly-Pro-p-nitroanilide-cleaving peptidases as well, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances or of at least one pharmaceutical or cosmetic composition containing at least one such substance for a prophylaxis or a therapy of diseases, particularly for a prophylaxis and a therapy of diseases accompanied by an excessive immune response (autoimmune diseases, allergies, transplant rejections), of other chronic-inflammatory diseases, of neuronal diseases and cerebral damage, of skin diseases (inter alia acne, psoriasis), of tumor diseases and of specific virus infections (inter alia SARS).
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: September 11, 2012
    Assignees: IMTM GmbH, Keyneurotek Pharmaceuticals AG
    Inventors: Siegfried Ansorge, Ute Bank, Karsten Nordhoff, Michael Taeger, Frank Striggow
  • Patent number: 7858655
    Abstract: The present invention concerns the use of Provided is a drug composition and a method for using the composition for the prevention and the therapy of neurodegenerative diseases. The combination comprises at least two of the following substances: ?-lipoic acid; ambroxol and one or several inhibitor(s) of the angiotension-converting enzyme (ACE).
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: December 28, 2010
    Assignee: Keyneurotek Pharmaceuticals AG
    Inventors: Peter Röhnert, Frank Striggow, Klaus Reymann, Siegfried Ansorge, Michael Täger, Ulrich Schröder
  • Patent number: 7645461
    Abstract: The invention relates to the use of the hydrogenation products of frankincense (olibanum), its hydrogenated ingredients as well as physiologically acceptable salts and derivatives thereof and hydrogenated frankincense extracts for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia, cranial/brain trauma and/or Alzheimer's disease. The use of frankincense, frankincense extract, substances contained in frankincense, their physiologically acceptable salts, their derivatives and the physiological salts thereof, pure boswellic acids, tirucallic acids or other triterpenes, their physiologically acceptable salts, derivatives of the salts thereof for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia and/or cranial/brain trauma is also provided according to the invention.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: January 12, 2010
    Assignee: Key Neurotek AG
    Inventors: Frank Striggow, Werner Schmidt, Till Mack
  • Publication number: 20090247898
    Abstract: The present invention refers to a device for measuring impedance in organotypic tissue comprising at least one recording chamber with a liquid permeable membrane supporting the organotypic tissue, at least one bottom electrode and at least one top electrode, wherein the liquid permeable membrane divides the recording chamber into a top chamber and a bottom chamber, wherein at least the bottom chamber contains culture medium for the organotypic tissue, and the bottom electrode(s) is/are located in the bottom chamber and the top electrode(s) is/are located in the top chamber, and wherein the organotypic tissue is located between the bottom electrode(s) and the top electrode(s). The present invention also refers to the use of the device according to the present invention for measuring impedance in organotypic tissue.
    Type: Application
    Filed: February 24, 2009
    Publication date: October 1, 2009
    Applicant: KeyNeurotek Pharmaceuticals AG
    Inventors: Andrea ROBITZKI, Andree Rothermel, Heinz-Georg Jahnke, Ina Sternberger, Frank Striggow, Till Mack
  • Publication number: 20080138811
    Abstract: The present invention relates to modified brain slice cultures and assay systems based thereon. In particular, the invention relates to a tissue-based assay system for screening agents capable of modulating etiopathology of neuronal cells, in particular in the context of Alzheimer's disease related brain lesions.
    Type: Application
    Filed: December 8, 2006
    Publication date: June 12, 2008
    Inventors: Till Mack, Frank Striggow, Ina Hinners
  • Publication number: 20080118475
    Abstract: Live cells obtained from a mammalian tissue or organ. The cells are maintained ex vivo on a porous membrane having a pore size of ?0.02 ?m at a physiologically acceptable pH, in the presence of a culture gas, in culture and in a culture medium. The inter-neighbour relationships and the signal transduction between the cells are retained.
    Type: Application
    Filed: September 22, 2005
    Publication date: May 22, 2008
    Applicant: KEYNEUROTEK AG
    Inventors: Frank Striggow, Till Mack, Peter Roehnert
  • Patent number: 7291599
    Abstract: The invention relates to a process for the treatment of neurodegenerative diseases wherein mis-folded proteins accumulate in characteristic lesions and contribute substantially to a pathogenesis and to an inflammatory reaction magnifying the damage, by the isolated or joint effect of inhibitors of the alanyl amino peptidase (APN) and of the dipeptidyl peptidase N (DP IV). Our results show that the application of inhibitors of the above-referenced enzymes or of preparations and dosage forms containing such inhibitors is definitely suitable for a therapy and prevention of dementia diseases and conditions.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: November 6, 2007
    Assignee: Keyneurotek AG
    Inventors: Frank Striggow, Peter Rohnert, Till Mack
  • Publication number: 20070078130
    Abstract: The present invention relates to substances capable of specifically inhibiting Ala-p-nitroanilide-cleaving peptidases and Gly-Pro-p-nitroanilide-cleaving peptidases as well, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances or of at least one pharmaceutical or cosmetic composition containing at least one such substance for a prophylaxis or a therapy of diseases, particularly for a prophylaxis and a therapy of diseases accompanied by an excessive immune response (autoimmune diseases, allergies, transplant rejections), of other chronic-inflammatory diseases, of neuronal diseases and cerebral damage, of skin diseases (inter alia acne, psoriasis), of tumor diseases and of specific virus infections (inter alia SARS).
    Type: Application
    Filed: October 15, 2004
    Publication date: April 5, 2007
    Inventors: Siegfried Ansorge, Ute Bank, Michael Taeger, Frank Striggow
  • Publication number: 20070037752
    Abstract: The invention relates to substances which specifically inhibit peptidases splitting ala-p-nitroanilide for use in medicine. The invention further relates to the use of at least one such substance or of a pharmaceutical or cosmetic composition containing at least one such substance for the prophylaxis and therapy of diseases, in particular the prophylaxis and therapy of diseases with an overshooting immune response (autoimmune diseases, allergies and transplant rejections), of other chronic inflammatory diseases, neuronal diseases and brain damages, skin diseases (acne and psoriasis, among others), tumor diseases and special virus infections (including SARS).
    Type: Application
    Filed: October 15, 2004
    Publication date: February 15, 2007
    Inventors: Siegfried Ansorge, Ute Bank, Karsten Nordhoff, Michael Taeger, Frank Striggow
  • Publication number: 20070037785
    Abstract: The present invention relates to substances capable of specifically inhibiting Gly-Pro-p-nitroanilide cleaving peptidases, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances or of at least one pharmaceutical or cosmetic composition containing at least one such substance for a prophylaxis or a therapy of diseases, particularly for a prophylaxis and a therapy of diseases accompanied by an excessive immune response (autoimmune diseases, allergies, transplant rejections), of other chronic-inflammatory diseases, of neuronal diseases and cerebral damage, of skin diseases (inter alia acne, psoriasis), of tumor diseases and of specific virus infections (inter alia SARS).
    Type: Application
    Filed: October 15, 2004
    Publication date: February 15, 2007
    Inventors: Siegfried Ansorge, Ute Bank, Karsten Nordhoff, Michael Taeger, Frank Striggow
  • Publication number: 20070005169
    Abstract: The present invention relates to a device for automatically carrying out laboratory operations on cell or tissue samples, which comprises a plurality of modular stations, each of which carries out at least one operation in a total sequence of operations, and at least one support unit for transporting sample containers to and between the stations, the device having at least one station for automatically changing liquid media in the sample containers.
    Type: Application
    Filed: September 24, 2004
    Publication date: January 4, 2007
    Inventors: Peter Röhnert, Frank Striggow
  • Publication number: 20060177467
    Abstract: The invention relates to the use of the hydrogenation products of frankincense (olibanum), its hydrogenated ingredients as well as physiologically acceptable salts and derivatives thereof and hydrogenated frankincense extracts for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia, cranial/brain trauma and/or Alzheimer's disease. The use of frankincense, frankincense extract, substances contained in frankincense, their physiologically acceptable salts, their derivatives and the physiological salts thereof, pure boswellic acids, tirucallic acids or other triterpenes, their physiologically acceptable salts, derivatives of the salts thereof for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia and/or cranial/brain trauma is also provided according to the invention.
    Type: Application
    Filed: March 18, 2004
    Publication date: August 10, 2006
    Inventors: Frank Striggow, Werner Schmidt, Till Mack
  • Publication number: 20050239039
    Abstract: The present invention relates to vital mammalian heart tissue cells maintained ex vivo while simulating physiological conditions, particularly vital mammalian heart tissue cells maintained ex vivo in a usual culture medium with the addition of a culture gas at a physiologically acceptable pH value, processes for their collection and for their cultivation as well as their use in model investigations of chemical, biological and/or physical influences on physiological or pathophysiological processes.
    Type: Application
    Filed: May 21, 2004
    Publication date: October 27, 2005
    Inventors: Andreas Goette, Peter Rohnert, Uwe Lendeckel, Frank Striggow
  • Publication number: 20050113310
    Abstract: The invention relates to a process for the treatment of neurodegenerative diseases wherein mis-folded proteins accumulate in characteristic lesions and contribute substantially to a pathogenesis and to an inflammatory reaction magnifying the damage, by the isolated or joint effect of inhibitors of the alanyl amino peptidase (APN) and of the dipeptidyl peptidase N (DP IV). Our results show that the application of inhibitors of the above-referenced enzymes or of preparations and dosage forms containing such inhibitors is definitely suitable for a therapy and prevention of dementia diseases and conditions.
    Type: Application
    Filed: August 11, 2004
    Publication date: May 26, 2005
    Inventors: Frank Striggow, Peter Rohnert, Till Mack
  • Publication number: 20040219207
    Abstract: A drug composition for the prevention and the therapy of neurodegenerative diseases (for example ischemic or hemorrhagic stroke, focal and global ischemia, amyotrophic lateral slerosis (ALS), Alzheimer's disease, Parkinson's disease, Hunntington's disease, multiple sclerosis). The combination of effective agents comprises at least two of the following substances: &agr;-lipoic acid; ambroxol and one or several inhibitor(s) of the angiotensin-converting enzyme (ACE). It could surprisingly be found in the experiments on which the invention is based that neuronal cells which are particularly sensitive to degenerative insults, have less free constitutional thiol groups than have other cells of the central nervous system (CNS). It was demonstrated that this reduced content of free thiol groups is causally connected to the damaging of those cells after a degenerative event.
    Type: Application
    Filed: January 26, 2004
    Publication date: November 4, 2004
    Inventors: Peter Rohnert, Frank Striggow, Klaus Reymann, Siegfried Ansorge, Michael Tager, Ulrich Schroder